CN107074778B - 苯并咪唑类似物和相关方法 - Google Patents

苯并咪唑类似物和相关方法 Download PDF

Info

Publication number
CN107074778B
CN107074778B CN201580030300.7A CN201580030300A CN107074778B CN 107074778 B CN107074778 B CN 107074778B CN 201580030300 A CN201580030300 A CN 201580030300A CN 107074778 B CN107074778 B CN 107074778B
Authority
CN
China
Prior art keywords
ret
phenyl
benzo
compound
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580030300.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074778A (zh
Inventor
李红雨
B·弗莱特
M·桑托罗
F·卡尔罗马格诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delhi Ii, University of
University of Arizona
Original Assignee
Delhi Ii, University of
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delhi Ii, University of, University of Arizona filed Critical Delhi Ii, University of
Publication of CN107074778A publication Critical patent/CN107074778A/zh
Application granted granted Critical
Publication of CN107074778B publication Critical patent/CN107074778B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201580030300.7A 2014-06-03 2015-06-03 苯并咪唑类似物和相关方法 Active CN107074778B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007321P 2014-06-03 2014-06-03
US62/007,321 2014-06-03
PCT/US2015/033962 WO2015187818A1 (en) 2014-06-03 2015-06-03 Benzimidazole analogues and related methods

Publications (2)

Publication Number Publication Date
CN107074778A CN107074778A (zh) 2017-08-18
CN107074778B true CN107074778B (zh) 2019-12-13

Family

ID=54767311

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580030300.7A Active CN107074778B (zh) 2014-06-03 2015-06-03 苯并咪唑类似物和相关方法

Country Status (7)

Country Link
US (1) US9988371B2 (enExample)
EP (1) EP3152194B8 (enExample)
JP (1) JP6612857B2 (enExample)
CN (1) CN107074778B (enExample)
AU (1) AU2015271692B2 (enExample)
ES (1) ES2742192T3 (enExample)
WO (1) WO2015187818A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107176951A (zh) * 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US12054483B2 (en) 2018-09-28 2024-08-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2020168963A1 (zh) * 2019-02-18 2020-08-27 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
CN113557235B (zh) * 2019-03-06 2025-08-08 C4医药公司 用于药物治疗的杂环化合物
CN112300106B (zh) * 2020-10-30 2023-03-03 徐州医科大学 一种蛋白激酶抑制剂及制备方法与应用
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
CN115198256A (zh) * 2022-07-13 2022-10-18 上海天承化学有限公司 一种用于聚酰亚胺薄膜的化学镀铜用还原液及其制备方法和应用
WO2024206989A2 (en) * 2023-03-30 2024-10-03 Bioventures, Llc Flt3 inhibitors and methods of using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128461A (zh) * 2005-02-24 2008-02-20 伊莱利利公司 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物
CN101198607A (zh) * 2005-04-14 2008-06-11 诺瓦提斯公司 适于作为蛋白激酶抑制剂的苯乙酰胺类
US20120135953A1 (en) * 2009-08-07 2012-05-31 Tibotec Pharmaceuticals Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors
CN102741241A (zh) * 2009-11-04 2012-10-17 爱尔兰詹森研发公司 苯并咪唑-咪唑衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225054A1 (en) 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
US20050171171A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
WO2011150201A2 (en) * 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013019682A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128461A (zh) * 2005-02-24 2008-02-20 伊莱利利公司 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物
CN101198607A (zh) * 2005-04-14 2008-06-11 诺瓦提斯公司 适于作为蛋白激酶抑制剂的苯乙酰胺类
US20120135953A1 (en) * 2009-08-07 2012-05-31 Tibotec Pharmaceuticals Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors
CN102741241A (zh) * 2009-11-04 2012-10-17 爱尔兰詹森研发公司 苯并咪唑-咪唑衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Solid-phase synthesis of benzimidazole libraries biased for RNA targets;Dionisios Vourloumis et al.;《Tetrahedron Letters》;20031231;第44卷;第2807-2811页 *

Also Published As

Publication number Publication date
WO2015187818A1 (en) 2015-12-10
US9988371B2 (en) 2018-06-05
CN107074778A (zh) 2017-08-18
AU2015271692B2 (en) 2019-05-23
JP6612857B2 (ja) 2019-11-27
ES2742192T3 (es) 2020-02-13
US20170101401A1 (en) 2017-04-13
EP3152194A4 (en) 2018-01-24
AU2015271692A1 (en) 2016-12-22
EP3152194B8 (en) 2019-10-09
EP3152194B1 (en) 2019-05-15
EP3152194A1 (en) 2017-04-12
JP2017519818A (ja) 2017-07-20

Similar Documents

Publication Publication Date Title
CN107074778B (zh) 苯并咪唑类似物和相关方法
TWI726968B (zh) Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
CN102977014B (zh) 新的喹啉类化合物及其用途
CN110831927B (zh) 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物
JP2020526499A (ja) Ｅｇｆｒチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
WO2018045957A1 (zh) 一种cdk4/6抑制剂及其制备方法和应用
TW201504233A (zh) 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
JP2020532561A (ja) Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
CN103313970B (zh) 新型二环式化合物或其盐
US11446287B2 (en) Compounds and methods for EP300 or CBP modulation and indications therefor
CN108239071B (zh) 酰胺及硫代酰胺类衍生物及其制备方法和应用
WO2020208139A1 (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
US20160024083A1 (en) Compounds and methods for treating cancers
JP6386585B2 (ja) プロテインキナーゼのインヒビターとしてのフロピリジン
EA018716B1 (ru) Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
WO2021185298A1 (zh) Egfr酪氨酸激酶抑制剂及其用途
CN111662275B (zh) 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
CN110407839A (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
EA027058B1 (ru) Терапевтическое применение имидазопиридиновых производных соединений
HK1242677B (zh) 苯并咪唑类似物和相关方法
HK1242677A1 (en) Benzimidazole analogues and related methods
CN113493436B (zh) 胺基取代吡啶衍生物及其制法和药物组合物与用途
TWI707853B (zh) 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途
WO2024094016A1 (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
US20160368872A1 (en) Compounds and methods for treating cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242677

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant